Inflammatory Comorbidity of Upper and Lower Airways: Epidemiology, Mechanism, and Therapeutic Advances of Rhinitis Combined with Asthma.

IF 2.3 4区 医学 Q3 ALLERGY
Kang Wang, Yan Qin, Jun Liu
{"title":"Inflammatory Comorbidity of Upper and Lower Airways: Epidemiology, Mechanism, and Therapeutic Advances of Rhinitis Combined with Asthma.","authors":"Kang Wang, Yan Qin, Jun Liu","doi":"10.1159/iaa/adfag019","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Asthma and rhinitis are the most common chronic inflammatory diseases of the lower and upper airways, respectively, and frequently coexist as inflammatory disorders of the same respiratory tract. However, the relationship between these two conditions is not simply unidirectional, and the underlying mechanisms remain incompletely understood.</p><p><strong>Summary: </strong>Approximately 80% of asthma patients have comorbid rhinitis, whereas 30-40% of rhinitis patients develop asthma, with comorbidities associated with greater symptom burden, reduced quality of life, and higher healthcare costs. The underlying mechanisms involve shared type 2 inflammation, neural reflexes, and systemic inflammatory spread. However, emerging evidence reveals significant clinical and therapeutic discordance between the upper and lower airways: biologics targeting the same type 2 pathway show differential efficacy, and only a subset of rhinitis patients progress to asthma. These findings challenge the one airway, one disease model and support conceptualizing the relationship as an overlap syndrome with both shared and distinct components. Current management has evolved toward an integrated strategy, with combined nasal and inhaled glucocorticoids as the cornerstone, leukotriene receptor antagonists offering additional benefits, and biologic agents (anti-IgE, anti-IL-4Rα) together with allergen immunotherapy providing targeted or etiological options.</p><p><strong>Key messages: </strong>The rhinitis-asthma comorbidity involves shared type 2 inflammation but also exhibits compartment-specific molecular and therapeutic differences. Biologic agents show discordant efficacy between upper and lower airways, underscoring the need for phenotype-driven endotyping rather than a one-size-fits-all approach. Future research should focus on compartment-specific biomarkers and precision management strategies to optimize outcomes for patients with airway comorbidities.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1"},"PeriodicalIF":2.3000,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/iaa/adfag019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Asthma and rhinitis are the most common chronic inflammatory diseases of the lower and upper airways, respectively, and frequently coexist as inflammatory disorders of the same respiratory tract. However, the relationship between these two conditions is not simply unidirectional, and the underlying mechanisms remain incompletely understood.

Summary: Approximately 80% of asthma patients have comorbid rhinitis, whereas 30-40% of rhinitis patients develop asthma, with comorbidities associated with greater symptom burden, reduced quality of life, and higher healthcare costs. The underlying mechanisms involve shared type 2 inflammation, neural reflexes, and systemic inflammatory spread. However, emerging evidence reveals significant clinical and therapeutic discordance between the upper and lower airways: biologics targeting the same type 2 pathway show differential efficacy, and only a subset of rhinitis patients progress to asthma. These findings challenge the one airway, one disease model and support conceptualizing the relationship as an overlap syndrome with both shared and distinct components. Current management has evolved toward an integrated strategy, with combined nasal and inhaled glucocorticoids as the cornerstone, leukotriene receptor antagonists offering additional benefits, and biologic agents (anti-IgE, anti-IL-4Rα) together with allergen immunotherapy providing targeted or etiological options.

Key messages: The rhinitis-asthma comorbidity involves shared type 2 inflammation but also exhibits compartment-specific molecular and therapeutic differences. Biologic agents show discordant efficacy between upper and lower airways, underscoring the need for phenotype-driven endotyping rather than a one-size-fits-all approach. Future research should focus on compartment-specific biomarkers and precision management strategies to optimize outcomes for patients with airway comorbidities.

上、下气道炎症共病:鼻炎合并哮喘的流行病学、机制及治疗进展。
哮喘和鼻炎分别是下呼吸道和上呼吸道最常见的慢性炎症性疾病。这两种情况经常共存为上、下气道炎症性疾病。临床资料普遍表明,哮喘患者合并鼻炎或鼻炎患者合并哮喘的合并症显著增加了患者的疾病负担。核心机制包括2型炎症通路、神经反射连锁和全身炎症传播。目前,鼻炎合并哮喘的治疗已转向综合治疗。鼻用和吸入联合使用糖皮质激素是基础治疗,白三烯受体拮抗剂是治疗合并症的有利药物。靶向生物制剂如抗免疫球蛋白E和抗白细胞介素4受体α单克隆抗体实现了对关键途径的精确干预,而过敏原免疫治疗提供了病因治疗的潜力。本文就该合并症的流行病学特点、病理生理机制及治疗进展进行综述,以期为今后合并症的治疗提供理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.60%
发文量
105
审稿时长
2 months
期刊介绍: ''International Archives of Allergy and Immunology'' provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书